Order Article Reprints

Bracht JWP, Karachaliou N, Bivona T, Lanman RB, Faull I, Nagy RJ, Drozdowskyj A, Berenguer J, Fernandez-Bruno M, Molina-Vila MA, et al. BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. Cancers. 2019; 11(9):1381. https://doi.org/10.3390/cancers11091381

Bracht, Jillian Wilhelmina Paulina, Niki Karachaliou, Trever Bivona, Richard B. Lanman, Iris Faull, Rebecca J. Nagy, Ana Drozdowskyj, Jordi Berenguer, Manuel Fernandez-Bruno, Miguel Angel Molina-Vila, and et al. 2019. "BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale" Cancers 11, no. 9: 1381. https://doi.org/10.3390/cancers11091381

Bracht, J. W. P., Karachaliou, N., Bivona, T., Lanman, R. B., Faull, I., Nagy, R. J., Drozdowskyj, A., Berenguer, J., Fernandez-Bruno, M., Molina-Vila, M. A., & Rosell, R. (2019). BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. Cancers, 11(9), 1381. https://doi.org/10.3390/cancers11091381